Wright Medical Group N.V. (WMGI - Free Report) has recently announced better-than-expected preliminary net sales results for fourth-quarter fiscal 2017. The company is likely to report full financial results on Feb 27, 2018, after the market closes.
The company expects net sales for fourth-quarter 2017 to be approximately $217.6 million, up 12.7% on a reported basis and 11.2% on a constant-currency basis, beating the Zacks Consensus Estimate of $216.94 million by a close margin.
For full-year 2017, Wright Medical’s preliminary net sales figure of $745 million lags the Zacks Consensus Estimate of $753.39 million. However, the 8% growth expectation (both reported and constant-currency basis) over the year-ago reported sales number is encouraging for investors.
Wright Medical Group N.V. Price and Consensus
The company has strong expectations from the integration of PERFORM Reversed launch and the recently acquired BLUEPRINT, projected to deliver strong shoulder sales growth in fiscal 2018. Since its inception in the first half of fiscal 2017, BLUEPRINT led to a sharp increase in the number of surgeons using the software to plan cases and the total number of cases planned.
However, the company did not benefit from the lower extremities business in the fourth quarter. Further, they had supply constraints related to a third-party coating vendor.
Despite a drag in the sales of the core U.S. lower extremities segment, the company is optimistic about restoring growth in 2018 on the back of improvement in execution and building their physician relationships.
Zacks Rank & Key Picks
Wright Medical carries a Zacks Rank #4 (Sell).
A few better-ranked stocks in the broader medical space are, Bio-Rad Laboratories Inc. (BIO - Free Report) , Centene Corporation (CNC - Free Report) and ABIOMED Inc. (ABMD - Free Report) . While Bio-Rad and Centene sport a Zacks Rank #1 (Strong Buy), ABIOMED carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank Stocks Here.
Bio-Rad’s long-term growth rate is 25%. The stock has rallied 11.3%, as against the industry’s gain of 7% over the last six months.
Centene’s long-term growth rate is 14%. The stock has rallied 29.3% compared with the industry’s gain of 18.9%, over the last six months.
ABIOMED’s long-term growth rate is an impressive 31.5%. The stock has gained 47.2%, much above the industry’s rally of 7.8%, over the last six months.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Click here for Zacks' private trades >>